Join Vera Therapeutics for a virtual investor event featuring Jonathan Barratt, MD, PhD, FRCP (University of Leicester), along with Vera’s management team, who will discuss long-term data from the Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), showing atacicept stabilized kidney function through 96 weeks. These data were presented over the weekend in a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024, held in San Diego, California, and simultaneously published in a manuscript in the Journal of the American Society of Nephrology.

A live question and answer session will follow the formal presentation.